S&P 500   3,896.66 (-0.13%)
DOW   31,577.05 (+0.13%)
QQQ   321.68 (-0.59%)
AAPL   126.50 (-1.01%)
MSFT   235.05 (-0.80%)
FB   265.39 (+0.18%)
GOOGL   2,079.25 (+0.46%)
TSLA   704.95 (-1.88%)
AMZN   3,143.58 (-0.08%)
NVDA   546.15 (-1.36%)
BABA   238.24 (-1.43%)
CGC   35.84 (+3.20%)
GE   13.06 (-0.38%)
MU   92.41 (-2.48%)
NIO   44.02 (-11.54%)
AMD   85.71 (-0.79%)
T   28.35 (+0.93%)
F   12.55 (+4.76%)
ACB   11.48 (+3.99%)
DIS   194.79 (-0.10%)
BA   224.42 (+0.01%)
NFLX   552.50 (+0.34%)
BAC   35.62 (-0.47%)
S&P 500   3,896.66 (-0.13%)
DOW   31,577.05 (+0.13%)
QQQ   321.68 (-0.59%)
AAPL   126.50 (-1.01%)
MSFT   235.05 (-0.80%)
FB   265.39 (+0.18%)
GOOGL   2,079.25 (+0.46%)
TSLA   704.95 (-1.88%)
AMZN   3,143.58 (-0.08%)
NVDA   546.15 (-1.36%)
BABA   238.24 (-1.43%)
CGC   35.84 (+3.20%)
GE   13.06 (-0.38%)
MU   92.41 (-2.48%)
NIO   44.02 (-11.54%)
AMD   85.71 (-0.79%)
T   28.35 (+0.93%)
F   12.55 (+4.76%)
ACB   11.48 (+3.99%)
DIS   194.79 (-0.10%)
BA   224.42 (+0.01%)
NFLX   552.50 (+0.34%)
BAC   35.62 (-0.47%)
S&P 500   3,896.66 (-0.13%)
DOW   31,577.05 (+0.13%)
QQQ   321.68 (-0.59%)
AAPL   126.50 (-1.01%)
MSFT   235.05 (-0.80%)
FB   265.39 (+0.18%)
GOOGL   2,079.25 (+0.46%)
TSLA   704.95 (-1.88%)
AMZN   3,143.58 (-0.08%)
NVDA   546.15 (-1.36%)
BABA   238.24 (-1.43%)
CGC   35.84 (+3.20%)
GE   13.06 (-0.38%)
MU   92.41 (-2.48%)
NIO   44.02 (-11.54%)
AMD   85.71 (-0.79%)
T   28.35 (+0.93%)
F   12.55 (+4.76%)
ACB   11.48 (+3.99%)
DIS   194.79 (-0.10%)
BA   224.42 (+0.01%)
NFLX   552.50 (+0.34%)
BAC   35.62 (-0.47%)
S&P 500   3,896.66 (-0.13%)
DOW   31,577.05 (+0.13%)
QQQ   321.68 (-0.59%)
AAPL   126.50 (-1.01%)
MSFT   235.05 (-0.80%)
FB   265.39 (+0.18%)
GOOGL   2,079.25 (+0.46%)
TSLA   704.95 (-1.88%)
AMZN   3,143.58 (-0.08%)
NVDA   546.15 (-1.36%)
BABA   238.24 (-1.43%)
CGC   35.84 (+3.20%)
GE   13.06 (-0.38%)
MU   92.41 (-2.48%)
NIO   44.02 (-11.54%)
AMD   85.71 (-0.79%)
T   28.35 (+0.93%)
F   12.55 (+4.76%)
ACB   11.48 (+3.99%)
DIS   194.79 (-0.10%)
BA   224.42 (+0.01%)
NFLX   552.50 (+0.34%)
BAC   35.62 (-0.47%)
Log in
NASDAQ:AFMD

Affimed Competitors

$5.77
-0.14 (-2.37 %)
(As of 03/2/2021 12:45 PM ET)
Add
Compare
Today's Range
$5.67
Now: $5.77
$5.93
50-Day Range
$5.27
MA: $6.15
$7.20
52-Week Range
$1.42
Now: $5.77
$7.48
Volume40,242 shs
Average Volume1.86 million shs
Market Capitalization$509.64 million
P/E RatioN/A
Dividend YieldN/A
Beta2.81

Competitors

Affimed (NASDAQ:AFMD) Vs. HRMY, STOK, KURA, AMTI, ADCT, and MCRB

Should you be buying AFMD stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Affimed, including Harmony Biosciences (HRMY), Stoke Therapeutics (STOK), Kura Oncology (KURA), Applied Molecular Transport (AMTI), ADC Therapeutics (ADCT), and Seres Therapeutics (MCRB).

Harmony Biosciences (NASDAQ:HRMY) and Affimed (NASDAQ:AFMD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Insider & Institutional Ownership

50.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 52.3% of Affimed shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Harmony Biosciences and Affimed's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harmony BiosciencesN/AN/AN/AN/AN/A
Affimed$23.96 million21.09$-36,250,000.00($0.56)-10.21

Harmony Biosciences has higher earnings, but lower revenue than Affimed.

Profitability

This table compares Harmony Biosciences and Affimed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Harmony BiosciencesN/AN/AN/A
Affimed-172.01%-99.24%-37.40%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Harmony Biosciences and Affimed, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Harmony Biosciences01202.67
Affimed00203.00

Harmony Biosciences presently has a consensus target price of $51.6667, indicating a potential upside of 43.28%. Affimed has a consensus target price of $9.50, indicating a potential upside of 65.79%. Given Affimed's stronger consensus rating and higher possible upside, analysts plainly believe Affimed is more favorable than Harmony Biosciences.

Summary

Affimed beats Harmony Biosciences on 4 of the 7 factors compared between the two stocks.

Stoke Therapeutics (NASDAQ:STOK) and Affimed (NASDAQ:AFMD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Stoke Therapeutics and Affimed, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stoke Therapeutics02702.78
Affimed00203.00

Stoke Therapeutics presently has a consensus target price of $62.1667, indicating a potential upside of 0.90%. Affimed has a consensus target price of $9.50, indicating a potential upside of 65.79%. Given Affimed's stronger consensus rating and higher probable upside, analysts clearly believe Affimed is more favorable than Stoke Therapeutics.

Earnings & Valuation

This table compares Stoke Therapeutics and Affimed's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stoke TherapeuticsN/AN/A$-32,330,000.00($1.80)-35.45
Affimed$23.96 million21.09$-36,250,000.00($0.56)-10.21

Stoke Therapeutics has higher earnings, but lower revenue than Affimed. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Stoke Therapeutics has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Affimed has a beta of 2.81, suggesting that its stock price is 181% more volatile than the S&P 500.

Insider & Institutional Ownership

52.3% of Affimed shares are held by institutional investors. 54.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Stoke Therapeutics and Affimed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stoke TherapeuticsN/A-22.93%-22.26%
Affimed-172.01%-99.24%-37.40%

Summary

Affimed beats Stoke Therapeutics on 7 of the 13 factors compared between the two stocks.

Affimed (NASDAQ:AFMD) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Volatility and Risk

Affimed has a beta of 2.81, indicating that its stock price is 181% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500.

Institutional & Insider Ownership

52.3% of Affimed shares are owned by institutional investors. Comparatively, 94.7% of Kura Oncology shares are owned by institutional investors. 11.0% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Affimed and Kura Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affimed00203.00
Kura Oncology011002.91

Affimed currently has a consensus target price of $9.50, suggesting a potential upside of 65.79%. Kura Oncology has a consensus target price of $39.5455, suggesting a potential upside of 33.19%. Given Affimed's stronger consensus rating and higher probable upside, analysts plainly believe Affimed is more favorable than Kura Oncology.

Profitability

This table compares Affimed and Kura Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Affimed-172.01%-99.24%-37.40%
Kura OncologyN/A-30.96%-28.02%

Earnings and Valuation

This table compares Affimed and Kura Oncology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Affimed$23.96 million21.09$-36,250,000.00($0.56)-10.21
Kura OncologyN/AN/A$-63,140,000.00($1.51)-19.86

Affimed has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.

Summary

Affimed beats Kura Oncology on 7 of the 13 factors compared between the two stocks.

Applied Molecular Transport (NASDAQ:AMTI) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Earnings & Valuation

This table compares Applied Molecular Transport and Affimed's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A
Affimed$23.96 million21.09$-36,250,000.00($0.56)-10.21

Applied Molecular Transport has higher earnings, but lower revenue than Affimed.

Insider & Institutional Ownership

52.0% of Applied Molecular Transport shares are held by institutional investors. Comparatively, 52.3% of Affimed shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for Applied Molecular Transport and Affimed, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Molecular Transport00303.00
Affimed00203.00

Applied Molecular Transport currently has a consensus target price of $48.6667, suggesting a potential downside of 13.10%. Affimed has a consensus target price of $9.50, suggesting a potential upside of 65.79%. Given Affimed's higher possible upside, analysts plainly believe Affimed is more favorable than Applied Molecular Transport.

Profitability

This table compares Applied Molecular Transport and Affimed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied Molecular TransportN/AN/AN/A
Affimed-172.01%-99.24%-37.40%

Summary

Applied Molecular Transport beats Affimed on 5 of the 8 factors compared between the two stocks.

Affimed (NASDAQ:AFMD) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Profitability

This table compares Affimed and ADC Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Affimed-172.01%-99.24%-37.40%
ADC TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Affimed and ADC Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affimed00203.00
ADC Therapeutics01402.80

Affimed currently has a consensus price target of $9.50, indicating a potential upside of 65.79%. ADC Therapeutics has a consensus price target of $47.50, indicating a potential upside of 75.08%. Given ADC Therapeutics' higher probable upside, analysts clearly believe ADC Therapeutics is more favorable than Affimed.

Insider & Institutional Ownership

52.3% of Affimed shares are owned by institutional investors. Comparatively, 40.9% of ADC Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Affimed and ADC Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Affimed$23.96 million21.09$-36,250,000.00($0.56)-10.21
ADC Therapeutics$2.34 million801.97$-116,480,000.00($2.36)-11.54

Affimed has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.

Affimed (NASDAQ:AFMD) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Volatility and Risk

Affimed has a beta of 2.81, suggesting that its share price is 181% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 4.07, suggesting that its share price is 307% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Affimed and Seres Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affimed00203.00
Seres Therapeutics02502.71

Affimed currently has a consensus price target of $9.50, indicating a potential upside of 65.79%. Seres Therapeutics has a consensus price target of $37.75, indicating a potential upside of 84.15%. Given Seres Therapeutics' higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than Affimed.

Earnings and Valuation

This table compares Affimed and Seres Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Affimed$23.96 million21.09$-36,250,000.00($0.56)-10.21
Seres Therapeutics$34.51 million53.78$-70,280,000.00($1.20)-16.95

Affimed has higher earnings, but lower revenue than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

52.3% of Affimed shares are owned by institutional investors. Comparatively, 94.3% of Seres Therapeutics shares are owned by institutional investors. 4.8% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Affimed and Seres Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Affimed-172.01%-99.24%-37.40%
Seres Therapeutics-385.22%-2,867.98%-51.24%


Affimed Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
HRMY
Harmony Biosciences
1.3$36.06-0.5%$2.06 billionN/A0.00Upcoming Earnings
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.0$63.81-4.2%$2.05 billionN/A-35.45
Kura Oncology logo
KURA
Kura Oncology
1.8$29.99-0.0%$1.99 billionN/A-18.40Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
1.3$56.42-0.3%$1.97 billionN/A0.00Upcoming Earnings
News Coverage
ADCT
ADC Therapeutics
1.6$27.24-0.3%$1.88 billion$2.34 million-11.54Upcoming Earnings
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.34-1.4%$1.88 billion$34.51 million-17.38News Coverage
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.7$26.85-1.1%$1.87 billion$103.54 million-20.19News Coverage
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
2.0$14.63-1.0%$1.84 billion$320,000.00-9.95Earnings Announcement
Analyst Revision
News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.44-0.1%$1.82 billionN/A-10.61Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.1$60.97-0.4%$1.81 billion$970,000.000.00Upcoming Earnings
Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$50.42-1.1%$1.79 billionN/A0.00News Coverage
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.5$26.39-1.6%$1.78 billion$410,000.00-5.74Analyst Report
ORGO
Organogenesis
1.0$16.86-2.7%$1.77 billion$260.98 million-281.00
Shattuck Labs logo
STTK
Shattuck Labs
1.1$40.93-2.6%$1.75 billionN/A0.00Upcoming Earnings
Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$35.32-1.0%$1.75 billionN/A-3.83
ImmunoGen logo
IMGN
ImmunoGen
1.3$9.16-2.3%$1.74 billion$82.27 million-22.34
Endo International logo
ENDP
Endo International
1.4$7.38-1.8%$1.73 billion$2.91 billion-10.85Earnings Announcement
Analyst Revision
Zymeworks logo
ZYME
Zymeworks
1.8$36.45-0.9%$1.70 billion$29.54 million-9.67Earnings Announcement
Increase in Short Interest
Analyst Revision
Gap Up
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$42.19-1.1%$1.69 billionN/A0.00Upcoming Earnings
uniQure logo
QURE
uniQure
1.9$38.63-1.5%$1.69 billion$7.28 million-10.25Earnings Announcement
Analyst Report
Kronos Bio logo
KRON
Kronos Bio
1.8$29.04-1.6%$1.65 billionN/A0.00Upcoming Earnings
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$18.00-0.5%$1.65 billion$145.97 million-7.29Earnings Announcement
Analyst Revision
News Coverage
ATBPD
Antibe Therapeutics
0.1$4.20-5.2%$1.63 billion$7.51 million-7.00
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.5$48.40-0.8%$1.62 billion$28.95 million-69.14
NKTX
Nkarta
1.6$50.13-2.0%$1.60 billionN/A0.00Upcoming Earnings
Gap Down
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.8$39.73-4.5%$1.59 billionN/A0.00Decrease in Short Interest
Gap Down
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.80-3.4%$1.56 billionN/A0.00Upcoming Earnings
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.4$29.73-2.8%$1.56 billion$175.34 million-17.49Earnings Announcement
Analyst Downgrade
News Coverage
Gap Up
OLMA
Olema Pharmaceuticals
1.7$39.25-3.0%$1.56 billionN/A0.00
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.22-0.8%$1.55 billion$1.63 billion12.73Earnings Announcement
Analyst Report
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.5$9.67-0.8%$1.54 billion$428.41 million14.01
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$21.71-0.8%$1.49 billionN/A-9.16Earnings Announcement
News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.4$19.27-1.0%$1.48 billion$4.23 million-10.77
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$33.08-1.4%$1.46 billion$6.20 million-14.51
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$35.92-0.6%$1.45 billionN/A-12.09Earnings Announcement
Analyst Report
Decrease in Short Interest
News Coverage
MacroGenics logo
MGNX
MacroGenics
1.4$24.81-0.6%$1.40 billion$64.19 million-7.93
Cytokinetics logo
CYTK
Cytokinetics
1.7$19.66-0.0%$1.39 billion$26.87 million-10.29Earnings Announcement
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$25.82-0.7%$1.37 billion$392.76 million10.71Earnings Announcement
Analyst Revision
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.4$54.51-2.2%$1.36 billionN/A-16.18Upcoming Earnings
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.6$20.15-1.8%$1.35 billion$42.12 million-14.93Earnings Announcement
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.7$28.17-4.7%$1.34 billionN/A-9.27Earnings Announcement
Gap Down
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.8$56.80-3.8%$1.34 billion$20.79 million-19.59Earnings Announcement
Analyst Report
News Coverage
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.6$46.25-0.2%$1.34 billionN/A-3.31
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$27.27-1.7%$1.28 billionN/A-10.06Earnings Announcement
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$54.86-8.7%$1.28 billionN/A-228.58Decrease in Short Interest
PLRX
Pliant Therapeutics
1.7$38.02-6.7%$1.26 billion$57.05 million0.00
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.62-1.8%$1.25 billionN/A0.00News Coverage
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.80-0.5%$1.24 billionN/A0.00Upcoming Earnings
Analyst Report
News Coverage
Avid Bioservices logo
CDMO
Avid Bioservices
1.4$21.46-1.4%$1.23 billion$59.70 million-214.60Upcoming Earnings
News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$11.39-2.6%$1.20 billion$120,000.00-4.22Upcoming Earnings
Gap Down
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.